CathWorks, a medical technology company based in Israel and California, announced that they received FDA clearance for the FFRangio System.

03 January 2019 Written by CN1699 Services Article viewed 10 times (1 times in the last week)

The FFRangio System is a non –invasive FFR platform, which precisely delivers multi-vessel physiological measurements to optimize intraprocuderal PCI therapy decisions.

For more details and uses visit CathWorks.

Image from CathWorks

Karen C

Off-Shore Manager - CN1699 Services